A share price of Aurinia Pharmaceuticals Inc [AUPH] is currently trading at $6.02, up 0.33%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AUPH shares have gain 7.69% over the last week, with a monthly amount drifted -24.66%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 27, February 2024, Aurinia to Participate in Upcoming Investor Healthcare Conferences. In a post published today on Yahoo Finance, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that management will be participating in the following upcoming investor conferences during the month of March:.
From an analyst’s perspective:
Aurinia Pharmaceuticals Inc [NASDAQ: AUPH] stock has seen the most recent analyst activity on November 04, 2022, when Oppenheimer downgraded its rating to a Perform. On December 10, 2021, upgrade upgraded it’s rating to Outperform and revised its price target to $31 on the stock. Oppenheimer downgraded its rating to a Perform but stick to its price target of $32 on October 28, 2021. H.C. Wainwright reiterated its recommendation of a Buy and raised its price target to $35 on January 25, 2021. H.C. Wainwright reiterated a Buy rating for this stock on November 03, 2020, and downed its price target to $28. In a note dated June 17, 2020, BTIG Research initiated an Buy rating and provided a target price of $20 on this stock.
Aurinia Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $5.35 and $12.43. Currently, Wall Street analysts expect the stock to reach $16.67 within the next 12 months. Aurinia Pharmaceuticals Inc [NASDAQ: AUPH] shares were valued at $6.02 at the most recent close of the market. An investor can expect a potential return of 176.91% based on the average AUPH price forecast.
Analyzing the AUPH fundamentals
Trailing Twelve Months sales for Aurinia Pharmaceuticals Inc [NASDAQ:AUPH] were 175.51M which represents 58.59% growth. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.89 points at the first support level, and at 5.76 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.13, and for the 2nd resistance point, it is at 6.25.
Aurinia Pharmaceuticals Inc [AUPH] reported earnings per share of -$0.19 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.16/share, meaning a difference of -$0.03 and a surprise factor of -18.80%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.09 per share as compared to estimates of -$0.17 per share, a difference of $0.08 representing a surprise of 47.10%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Aurinia Pharmaceuticals Inc [NASDAQ:AUPH] is 5.50. As well, the Quick Ratio is 4.99, while the Cash Ratio is 0.05. Considering the valuation of this stock, the price to sales ratio is 4.96, the price to book ratio is 2.29.
Transactions by insiders
Recent insider trading involved Knappertz Volker, EVP, Research and Development, that happened on Feb 20 when 25146.0 shares were sold. Chief Commercial Officer, Habig Scott Michael completed a deal on Feb 20 to sell 15867.0 shares. Meanwhile, Director Jayne David R.W. sold 8733.0 shares on May 23.
